NCT00195325终止1 期
A Phase 1 Dose Escalation Study of TTI-237 Administered Intravenously (IV) Once Weekly in Subjects With Advanced Malignant Solid Tumors.
Wyeth is now a wholly owned subsidiary of Pfizer3 个研究点 分布在 1 个国家目标入组 45 人开始时间: 2005年8月1日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 终止
- 发起方
- 入组人数
- 45
- 试验地点
- 3
- 主要终点
- To determine safety, tolerability, and MTD of TTI-237 - patients are monitored during the duration of their participation on the trial.
研究概览
简要总结
The purpose of this study is to evaluate the safety, tolerability, and MTD (maximum tolerated dose) of TTI-237 for the treatment of subjects with advanced malignant solid tumors.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Factorial
- 主要目的
- Educational Counseling Training
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Documented diagnosis of malignant solid tumor with measurable disease
- •Life expectancy of at least 12 weeks
- •ECOG (The Eastern Cooperative Oncology Group scale) performance status of 0, 1, or 2
排除标准
- •Recent major surgery, radiation therapy or anti-cancer treatment
- •History of any other prior malignancy within the last 5 years
结局指标
主要结局
To determine safety, tolerability, and MTD of TTI-237 - patients are monitored during the duration of their participation on the trial.
次要结局
- Preliminary pharmacokinetics (during cycle 1) and anti-tumor activity of TTI-237 (approximately every 8 weeks).
研究者
研究点 (3)
Loading locations...
相似试验
终止
1 期
Study Evaluating TTI-237 in Advanced Malignant Solid TumorsNeoplasmsNCT00195247Wyeth is now a wholly owned subsidiary of Pfizer45
终止
2 期
Safety & Efficacy Study of TPI 287 + Avastin in Adults With Glioblastoma That Progressed Following Prior Avastin TherapyGlioblastoma MultiformeNCT02047214Cortice Biosciences, Inc.17
已完成
1 期
Phase I Dose Escalating Study of TKI258Advanced Solid TumorsNCT01471548Novartis Pharmaceuticals31
已完成
1 期
Study of TAK-901 in Adults With Advanced Solid Tumors or LymphomaAdvanced Solid TumorsLymphomaNCT00935844Millennium Pharmaceuticals, Inc.20
已完成
1 期
A Study Evaluating BSI-201 in Combination With Chemotherapeutic Regimens in Subjects With Advanced Solid TumorsTumorsNCT00422682Sanofi136